Cooley Advises Alder Biopharmaceuticals on Initial Public Offering

Seattle – May 14, 2014 – Cooley LLP announced today that it advised Alder Biopharmaceuticals, Inc. on its $80 million initial public offering. Alder is a Washington-based clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder is currently developing two lead product candidates: ALD403, an investigational monoclonal antibody for migraine, and Clazakizumab, an investigational monoclonal antibody for rheumatoid arthritis and other autoimmune indications, in collaboration with Bristol-Myers Squibb.  The company now trades on the NASDAQ Global Stock Market under the symbol "ALDR."

The Cooley corporate and securities team advising Alder was led by partners Sonya Erickson and John McKenna and included associates Julia Conway, Alan Hambelton, Michael Pirog and Yuri Weigel. Critical support for the offering was provided by partners Renee Deming and Amy Wood and special counsel Jeannie Leahy (compensation & benefits); partners Natasha Leskovsek and Marya Postner (regulatory & licensing); and partners Mark Windfeld-Hansen and Susan Philpot (tax).

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Partner, San Francisco
John McKenna Partner, Palo Alto
Marya Postner Partner, Palo Alto
Amy M. Wood Partner, San Diego
Sonya Erickson Partner, Seattle
Natasha Leskovsek Partner, Washington, DC
Alan Hambelton Partner, Seattle
Renee Deming Retired Partner, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Julia Stark Associate, Seattle
Yuri Weigel Associate, Seattle